Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354

• Auteurs principaux: Tayla A. Rees (Auteur), Benjamin J. Buttle (Auteur), Zoe Tasma (Auteur), Sung-Hyun Yang (Auteur), Paul W. R. Harris (Auteur), Christopher S. Walker (Auteur)
• Format: Livre
• Publié: Frontiers Media S.A., 2024-10-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Type 2 diabetes (T2D) and obesity are prevalent metabolic disorders affecting millions of individuals worldwide. A new effective therapeutic drug called tirzepatide for the treatment of obesity and T2D is a dual agonist of the GIP receptor and GLP-1 receptor. Tirzepatide is clinically more effective...